## Convulsions Associated with the Use of a Synthetic Can

Journal of Medical Toxicology 8, 62-64 DOI: 10.1007/s13181-011-0182-2

Citation Report

#	Article	IF	CITATIONS
1	Internet Highs—Seizures After Consumption of Synthetic Cannabinoids Purchased Online. Journal of Addiction Medicine, 2012, 6, 240-241.	1.4	49
2	Spicy Seizure. American Journal of the Medical Sciences, 2012, 344, 67-68.	0.4	44
3	Adverse Effects and Detection of Synthetic Cannabinoids. American Journal on Addictions, 2012, 21, 568-569.	1.3	3
4	Synthetic Cannabis and Respiratory Depression. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 459-462.	0.7	40
5	Direct analysis in real time mass spectrometry with collisionâ€induced dissociation for structural analysis of synthetic cannabinoids. Rapid Communications in Mass Spectrometry, 2012, 26, 2335-2342.	0.7	60
6	Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 234-243.	2.5	393
7	Herbal Marijuana Alternatives and Bath Salts—"Barely Legal―Toxic Highs. Clinical Pediatric Emergency Medicine, 2012, 13, 283-291.	0.4	14
8	Synthetic Cannabinoid Use and Sudden Death. Academic Forensic Pathology, 2012, 2, 202-205.	0.3	3
10	Emerging Drugs of Abuse: What Was New Yesterday Is NEW Today. Journal of Medical Toxicology, 2012, 8, 1-2.	0.8	10
11			
	Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.	1.5	241
12	First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.	1.5 0.8	241 66
12 13	<ul> <li>Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.</li> <li>First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.</li> <li>Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.</li> </ul>	1.5 0.8	241 66 12
12 13 14	<ul> <li>Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.</li> <li>First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.</li> <li>Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.</li> <li>Updates in the General Approach to the Pediatric Poisoned Patient. Pediatric Clinics of North America, 2013, 60, 1203-1220.</li> </ul>	1.5 0.8 0.9	241 66 12 5
12 13 14 15	<ul> <li>Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.</li> <li>First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.</li> <li>Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.</li> <li>Updates in the General Approach to the Pediatric Poisoned Patient. Pediatric Clinics of North America, 2013, 60, 1203-1220.</li> <li>Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence, 2013, 131, 106-111.</li> </ul>	1.5 0.8 0.9 1.6	241 66 12 5 277
12 13 14 15	<ul> <li>Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.</li> <li>First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.</li> <li>Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.</li> <li>Updates in the General Approach to the Pediatric Poisoned Patient. Pediatric Clinics of North America, 2013, 60, 1203-1220.</li> <li>Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence, 2013, 131, 106-111.</li> <li>Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Analytical and Bioanalytical Chemistry, 2013, 405, 3937-3944.</li> </ul>	1.5 0.8 0.9 1.6 1.9	241 66 12 5 277 60
12 13 14 15 16	<ul> <li>Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.</li> <li>First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.</li> <li>Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.</li> <li>Updates in the Ceneral Approach to the Pediatric Poisoned Patient. Pediatric Clinics of North America, 2013, 60, 1203-1220.</li> <li>Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence, 2013, 131, 106-111.</li> <li>Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Analytical and Bioanalytical Chemistry, 2013, 405, 3937-3944.</li> <li>Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicology, 2013, 31, 86-92.</li> </ul>	1.5 0.8 0.9 1.6 1.9	241 66 12 5 277 60 25
12 13 14 15 16 17	<ul> <li>Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.</li> <li>First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.</li> <li>Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.</li> <li>Updates in the General Approach to the Pediatric Poisoned Patient. Pediatric Clinics of North America, 2013, 60, 1203-1220.</li> <li>Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence, 2013, 131, 106-111.</li> <li>Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Analytical and Bioanalytical Chemistry, 2013, 405, 3937-3944.</li> <li>Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicology, 2013, 31, 86-92.</li> <li>The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 2013, 4, 1081-1092.</li> </ul>	1.5 0.8 0.9 1.6 1.9 1.4 1.7	241 66 12 5 277 60 25 80

#	Article	IF	Citations
20	Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, 2013, 108, 534-544.	1.7	397
21	The 12â€month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Human Psychopharmacology, 2013, 28, 390-393.	0.7	72
22	Emergency Physicians' Knowledge of Cannabinoid Designer Drugs. Western Journal of Emergency Medicine, 2013, 14, 467-470.	0.6	27
23	Synthetic cannabinomimetics and †legal highs'. Journal of Pharmacy Practice and Research, 2014, 44, 238-239.	0.5	0
24	Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Current Addiction Reports, 2014, 1, 129-136.	1.6	95
25	Emerging Drugs of Abuse. Emergency Medicine Clinics of North America, 2014, 32, 1-28.	0.5	96
26	Spicing up the military: Use and effects of synthetic cannabis in substance abusing army personnel. Addictive Behaviors, 2014, 39, 1139-1144.	1.7	16
27	Spice/K2 drugs – more than innocent substitutes for marijuana. International Journal of Neuropsychopharmacology, 2014, 17, 509-525.	1.0	79
28	Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 2014, 144, 12-41.	1.6	572
29	JWH-018 in rhesus monkeys: Differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. European Journal of Pharmacology, 2014, 740, 151-159.	1.7	26
30	Emerging drugs of abuse. Disease-a-Month, 2014, 60, 110-132.	0.4	35
31	Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series. Journal of Dual Diagnosis, 2014, 10, 168-173.	0.7	45
32	Driving under the influence of synthetic cannabinoids ("Spiceâ€ <del>)</del> : a case series. International Journal of Legal Medicine, 2014, 128, 59-64.	1.2	101
34	"Street―and Prescription Drug Abuse. , 0, , 1267-1282.		0
35	Cannabis sintético: aspectos toxicológicos, usos clÃnicos y droga de diseño. Revista Facultad De Medicina, 2015, 63, 501-510.	0.0	5
36	Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 2015, 33, 355-366.	1.4	26
37	A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA. Journal of Emergency Medicine, 2015, 48, 573-580.	0.3	81
38	Toxin-Induced Seizures. , 2015, , 1-27.		0

CITATION REPORT

ARTICLE IF CITATIONS # The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal 39 2.0 211 of Psychopharmacology, 2015, 29, 254-263. JWH-018 impairs sensorimotor functions in mice. Neuroscience, 2015, 300, 174-188. 1.1 59 Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice. Neuropharmacology, 41 2.0 81 2015, 95, 68-82. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in 103 a large global sample. Journal of Psychopharmacology, 2015, 29, 698-703. Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids?. Forensic 43 1.3 82 Science International, 2015, 257, e6-e11. Les cannabinoÃ<sup>-</sup>des de synthÃ<sup>··</sup>seÂ: épidémiologie, modalités de consommations et effets cliniques. Toxicologie Analytique Et Clinique, 2015, 27, 33-40. 0.1 Toxicology and Management of Novel Psychoactive Drugs. Journal of Pharmacy Practice, 2015, 28, 45 0.5 71 50-65. Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Óbject Recognition in mice: Behavioral, electrophysiological and neurochemical evidence. 2.0 46 40 Neuropharmacology, 2016, 109, 254-269. Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic 47 0.4 33 toxicology. Toxicology Letters, 2016, 253, 7-16. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetradâ€; sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. 1.5 Psychopharmacology, 2016, 233, 3685-3709. Synthetic Cannabinoidsâ€"Further Evidence Supporting the Relationship Between Cannabinoids and 49 131 0.7 Psychosis. Biological Psychiatry, 2016, 79, 539-548. Drug Misuse in Adolescents Presenting to the Emergency Department. Pediatric Emergency Care, 2017, 33, 451-456. Synthetic Pot: Not Your Grandfather's Marijuana. Trends in Pharmacological Sciences, 2017, 38, 51 4.0 78 257-276. Pharmacoâ€toxicological effects of the novel thirdâ€generation fluorinate synthetic cannabinoids, <scp>5Fâ€ADBINACA</scp>, <scp>ABâ€FUBINACA</scp>, and <scp>STSâ€135</scp> in mice. In vitro and in vivo 0.7 studies. Human Psychopharmacology, 2017, 32, e2601. New-Onset Refractory Status Epilepticus Associated With the Use of Synthetic Cannabinoids. 53 2.511 Psychosomatics, 2017, 58, 180-186. Evaluation of the first seizure patient: Key points in the history and physical examination. Seizure: the 54 Journal of the British Epilepsy Association, 2017, 49, 54-63. Natural (â^†9-THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the 55 1.6 43 cannabinoid CB1 receptor. Scientific Reports, 2017, 7, 10516. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events. 1.2 Advances in Pharmacology, 2017, 80, 135-168.

CITATION REPORT

	CHAIL	N KEPORT	
#	Article	IF	Citations
57	Acute Effects of Synthetic Cannabinoids: Update 2015. Substance Abuse, 2017, 38, 344-366.	1.1	51
58	Chronic exposure to cannabinoids during adolescence causes longâ€lasting behavioral deficits in adult mice. Addiction Biology, 2017, 22, 1778-1789.	1.4	48
59	A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus—A case report and review of the literature. SAGE Open Medical Case Reports, 2017, 5, 2050313X1774520.	0.2	19
60	AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5â€2-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. Molecules, 2017, 22, 443.	1.7	12
61	The Endocannabinoid System as a Target for New Antiseizure Drugs. , 2017, , 606-615.		3
62	Synthetic cannabinoid AM2201 induces seizures: Involvement of cannabinoid CB 1 receptors and glutamatergic transmission. Toxicology and Applied Pharmacology, 2018, 338, 1-8.	1.3	41
63	Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ9-THC in Rats. Frontiers in Neuroscience, 2018, 12, 703.	1.4	17
64	Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Archives of Pharmacal Research, 2018, 41, 691-710.	2.7	43
65	Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids. Arhiv Za Higijenu Rada I Toksikologiju, 2018, 69, 178-185.	0.4	9
66	Clinical effects of reported synthetic cannabinoid exposure in patients admitted to the intensive care unit. American Journal of Emergency Medicine, 2019, 37, 1060-1064.	0.7	7
67	New-generation azaindole-adamantyl-derived synthetic cannabinoids. Forensic Toxicology, 2019, 37, 350-365.	1.4	11
68	Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 146-156.	1.3	21
69	Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication. International Ophthalmology, 2019, 39, 237-241.	0.6	2
70	DARK Classics in Chemical Neuroscience: Synthetic Cannabinoids (Spice/K2). ACS Chemical Neuroscience, 2020, 11, 3881-3892.	1.7	22
71	Synthetic cannabinoid receptor agonists-induced recurrent seizure in elderly patient. American Journal of Emergency Medicine, 2020, 38, 850.e5-850.e6.	0.7	3
72	Comparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Δ <sup>9</sup> -Tetrahydrocannabinol. Cannabis and Cannabinoid Research, 2020, 5, 32-41.	1.5	19
73	Δ9-tetrahydrocannabinol: Drug discrimination abuse liability testing in female Lister Hooded rats: Trials, tribulations and triumphs. Journal of Pharmacological and Toxicological Methods, 2020, 106, 106937.	0.3	2
74	Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacology Biochemistry and Behavior, 2020, 195, 172949.	1.3	15

CITATION REPORT

#	Article	IF	CITATIONS
75	Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model. Frontiers in Pharmacology, 2020, 11, 464.	1.6	20
76	Designer drugs: mechanism of action and adverse effects. Archives of Toxicology, 2020, 94, 1085-1133.	1.9	138
77	Nausea-Induced Conditioned Gaping Reactions in Rats Produced by High-Dose Synthetic Cannabinoid, JWH-018. Cannabis and Cannabinoid Research, 2020, 5, 298-304.	1.5	6
78	Cannabinoids and the eye. Survey of Ophthalmology, 2021, 66, 327-345.	1.7	21
79	Relation Between Acute Administration of Synthetic Cannabinoids and Induction of Epileptic Seizures. Addictive Disorders and Their Treatment, 2021, 20, 527-534.	0.5	0
80	Synthetic cannabinoids (SC). , 2022, , 415-446.		Ο
81	Substance Use Disorders: Cognitive Sequelae, Behavioral Manifestations, Neuroimaging Correlates, and Novel Interventions. , 2019, , 697-728.		2
82	Toxicant-Induced Seizures. , 2017, , 447-473.		2
83	Exploring the Relationships between Sexual Orientation and Gender Identity and Youth Synthetic Cannabinoid Use. Substance Use and Misuse, 2021, 56, 327-332.	0.7	4
84	Cannabis sativa Increases Seizure Severity and Brain Lipid Peroxidation in Pentylenetetrazole-Induced Kindling in Rats. Biomedical and Pharmacology Journal, 2018, 11, 1187-1197.	0.2	9
85	New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature. Current Pharmaceutical Design, 2014, 20, 4106-4111.	0.9	73
86	New synthetic cannabinoids are coming to the drug scene. Kontakt, 2012, 14, 369-377.	0.1	1
87	The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research, 2017, 5, 1-138.	0.5	12
88	Smoking Synthetic Marijuana Leads to Self-Mutilation Requiring Bilateral Amputations. Orthopedics, 2014, 37, e391-4.	0.5	40
90	Structure–activity relationships of valine, <i>tert</i> -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry, 2022, 13, 156-174.	1.7	11
93	The Potential Proconvulsant Effects of Cannabis: a Scoping Review. Journal of Medical Toxicology, 2022, , 1.	0.8	4
95	Synthetic Cannabinoids in Prisons: Content Analysis of TikToks. JMIR Infodemiology, 2022, 2, e37632.	1.0	0
96	Chronic Synthetic Marijuana Use: A Case of First-Onset Seizures as a Withdrawal Symptom. Health Psychology Research, 2022, 10, .	0.6	1

#	Article	IF	CITATIONS
97	Methyl (S)-2-(1–7 (5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (5F-MDMB-PICA) intoxication in a child with identification of two new metabolites (ultra-high-performance liquid) Tj ETQq0 0 0 rgB	T <b>‡Q</b> iverloc	ck <b>4</b> 10 Tf 50 7
98	Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice. Psychopharmacology, 0, , .	1.5	0
99	Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry, 0, 13, .	1.3	0
101	Introduction to addiction. , 2023, , 3-41.		0
102	The Uses of Cannabinoids in Medicine and Their Spectroscopic Applications. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 235-257.	0.1	0
103	Ethanol enhances JWH-018-induced impairment of sensorimotor and memory functions in mice: From preclinical evidence to forensic implication in Driving Under the Influence of Drugs. Drug and	1.6	1